ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,702.55
      -0.19%
      US Tech 100
      19,287.60
      -0.24%
      Dow Jones
      42,063.36
      0.09%
      Brent Oil
      74.135
      0.00%
      Bitcoin
      62,881.44
      -0.78%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. NewAmsterdam Pharma Company NV (NAMSW)

      7. NewAmsterdam Pharma Company NV (NAMSW) News

      NAMSW

      NewAmsterdam Pharma Comp... (NAMSW)

      NewAmsterdam Pharma Company NV
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:NAMSW
      DateTimeSourceHeadlineSymbolCompany
      09/06/20244:32PMGlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
      08/30/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in SeptemberNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      08/07/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial ResultsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      08/02/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
      07/29/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial HypercholesterolemiaNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      07/26/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024NASDAQ:NAMSWNewAmsterdam Pharma Company NV
      07/18/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of DirectorsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      07/08/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk FactorsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      07/03/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
      06/11/20248:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      06/11/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark OfficeNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      06/07/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      06/07/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
      05/29/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in JuneNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      05/21/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      05/09/20244:18PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      05/09/20244:15PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      05/09/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      05/09/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      05/08/20244:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
      05/03/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
      05/02/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024NASDAQ:NAMSWNewAmsterdam Pharma Company NV
      04/09/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      04/01/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      03/25/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      03/12/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      02/28/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      02/26/20248:00AMGlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      02/13/202410:40PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
      02/13/20244:01PMGlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
       Showing the most relevant articles for your search:NASDAQ:NAMSW